George Clark brings over 30 years of experience in analytical chemistry, toxicology, and molecular biology to (Xenobiotic Detection Systems) XDS. His education includes a Ph.D. in toxicology from the University of North Carolina at Chapel Hill, Masters degrees in immunology from the University of California at Berkeley and in Biochemistry from North Carolina State University. He worked for GlaxoSmithKline for 5 years and the National Institutes of Environmental Health Sciences for 14 years prior to becoming the President and founder of XDS along with Dr. Michael S. Denison in 1995. XDS has two patents covering their innovative technology for analysis of dioxin-like chemicals in biological and environmental samples. The XDS-CALUX® biotechnology for measuring dioxin-like chemicals has been validated worldwide in the European Union, Japan, and the United States. The company continues to develop new and novel technologies for protecting environmental and human health from exposure to xenobiotic environmental chemicals and biological hazards.